Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
Identifieur interne : 000246 ( Main/Exploration ); précédent : 000245; suivant : 000247Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
Auteurs : Jacobo Rogado [Espagne] ; Pedro Gull N [Espagne] ; Berta Obispo [Espagne] ; Gloria Serrano [Espagne] ; Miguel Lara [Espagne]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2021.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (usage thérapeutique), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Antinéoplasiques (usage thérapeutique), Antiviraux (usage thérapeutique), Association médicamenteuse (MeSH), Dexaméthasone (usage thérapeutique), Espagne (MeSH), Excrétion virale (MeSH), Facteurs de risque (MeSH), Facteurs temps (MeSH), Femelle (MeSH), Glucocorticoïdes (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (MeSH), Immunisation passive (MeSH), Immunothérapie (MeSH), Lopinavir (usage thérapeutique), Modèles des risques proportionnels (MeSH), Mâle (MeSH), Ritonavir (usage thérapeutique), Sujet âgé (MeSH), Thérapie moléculaire ciblée (MeSH), Tumeurs (anatomopathologie), Tumeurs (complications), Tumeurs (thérapie), Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (complications), Tumeurs du poumon (thérapie), Tumeurs du sein (anatomopathologie), Tumeurs du sein (complications), Tumeurs du sein (thérapie), Études de suivi (MeSH).
- MESH :
- analogues et dérivés : AMP, Alanine.
- anatomopathologie : Tumeurs, Tumeurs du poumon, Tumeurs du sein.
- thérapie : Tumeurs, Tumeurs du poumon, Tumeurs du sein.
- usage thérapeutique : AMP, Alanine, Antinéoplasiques, Antiviraux, Dexaméthasone, Glucocorticoïdes, Lopinavir, Ritonavir, Tumeurs, Tumeurs du poumon, Tumeurs du sein.
- Association médicamenteuse, Espagne, Excrétion virale, Facteurs de risque, Facteurs temps, Femelle, Humains, Hydroxychloroquine, Immunisation passive, Immunothérapie, Modèles des risques proportionnels, Mâle, Sujet âgé, Thérapie moléculaire ciblée, Études de suivi.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Aged (MeSH), Alanine (analogs & derivatives), Alanine (therapeutic use), Antineoplastic Agents (therapeutic use), Antiviral Agents (therapeutic use), Breast Neoplasms (complications), Breast Neoplasms (pathology), Breast Neoplasms (therapy), COVID-19 (complications), COVID-19 (diagnosis), COVID-19 (drug therapy), COVID-19 (therapy), COVID-19 Nucleic Acid Testing (MeSH), COVID-19 Serological Testing (MeSH), Dexamethasone (therapeutic use), Drug Combinations (MeSH), Female (MeSH), Follow-Up Studies (MeSH), Glucocorticoids (therapeutic use), Humans (MeSH), Hydroxychloroquine (MeSH), Immunization, Passive (MeSH), Immunotherapy (MeSH), Latent Infection (MeSH), Lopinavir (therapeutic use), Lung Neoplasms (complications), Lung Neoplasms (pathology), Lung Neoplasms (therapy), Male (MeSH), Molecular Targeted Therapy (MeSH), Neoplasms (complications), Neoplasms (pathology), Neoplasms (therapy), Proportional Hazards Models (MeSH), Risk Factors (MeSH), Ritonavir (therapeutic use), SARS-CoV-2 (MeSH), Spain (MeSH), Time Factors (MeSH), Virus Shedding (MeSH).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Antineoplastic Agents, Antiviral Agents, Dexamethasone, Glucocorticoids, Lopinavir, Ritonavir.
- geographic : Spain.
- complications : Breast Neoplasms, COVID-19, Lung Neoplasms, Neoplasms.
- diagnosis : COVID-19.
- drug therapy : COVID-19.
- pathology : Breast Neoplasms, Lung Neoplasms, Neoplasms.
- therapy : Breast Neoplasms, COVID-19, Lung Neoplasms, Neoplasms.
- Aged, COVID-19 Nucleic Acid Testing, COVID-19 Serological Testing, Drug Combinations, Female, Follow-Up Studies, Humans, Hydroxychloroquine, Immunization, Passive, Immunotherapy, Latent Infection, Male, Molecular Targeted Therapy, Proportional Hazards Models, Risk Factors, SARS-CoV-2, Time Factors, Virus Shedding.
DOI: 10.1016/j.ejca.2021.02.011
PubMed: 33735810
PubMed Central: PMC7901370
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.</title>
<author><name sortKey="Rogado, Jacobo" sort="Rogado, Jacobo" uniqKey="Rogado J" first="Jacobo" last="Rogado">Jacobo Rogado</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain. Electronic address: jacobo.rogado@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gull N, Pedro" sort="Gull N, Pedro" uniqKey="Gull N P" first="Pedro" last="Gull N">Pedro Gull N</name>
<affiliation wicri:level="3"><nlm:affiliation>Public Health and Epidemiology Research Group, Universidad de Alcalá, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Public Health and Epidemiology Research Group, Universidad de Alcalá, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Obispo, Berta" sort="Obispo, Berta" uniqKey="Obispo B" first="Berta" last="Obispo">Berta Obispo</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Serrano, Gloria" sort="Serrano, Gloria" uniqKey="Serrano G" first="Gloria" last="Serrano">Gloria Serrano</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lara, Miguel" sort="Lara, Miguel" uniqKey="Lara M" first="Miguel" last="Lara">Miguel Lara</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain; Universidad Complutense, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain; Universidad Complutense, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33735810</idno>
<idno type="pmid">33735810</idno>
<idno type="doi">10.1016/j.ejca.2021.02.011</idno>
<idno type="pmc">PMC7901370</idno>
<idno type="wicri:Area/Main/Corpus">000218</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000218</idno>
<idno type="wicri:Area/Main/Curation">000218</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000218</idno>
<idno type="wicri:Area/Main/Exploration">000218</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.</title>
<author><name sortKey="Rogado, Jacobo" sort="Rogado, Jacobo" uniqKey="Rogado J" first="Jacobo" last="Rogado">Jacobo Rogado</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain. Electronic address: jacobo.rogado@gmail.com.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gull N, Pedro" sort="Gull N, Pedro" uniqKey="Gull N P" first="Pedro" last="Gull N">Pedro Gull N</name>
<affiliation wicri:level="3"><nlm:affiliation>Public Health and Epidemiology Research Group, Universidad de Alcalá, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Public Health and Epidemiology Research Group, Universidad de Alcalá, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Obispo, Berta" sort="Obispo, Berta" uniqKey="Obispo B" first="Berta" last="Obispo">Berta Obispo</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Serrano, Gloria" sort="Serrano, Gloria" uniqKey="Serrano G" first="Gloria" last="Serrano">Gloria Serrano</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lara, Miguel" sort="Lara, Miguel" uniqKey="Lara M" first="Miguel" last="Lara">Miguel Lara</name>
<affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain; Universidad Complutense, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain; Universidad Complutense, Madrid</wicri:regionArea>
<placeName><settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">European journal of cancer (Oxford, England : 1990)</title>
<idno type="eISSN">1879-0852</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term>
<term>Adenosine Monophosphate (therapeutic use)</term>
<term>Aged (MeSH)</term>
<term>Alanine (analogs & derivatives)</term>
<term>Alanine (therapeutic use)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Breast Neoplasms (complications)</term>
<term>Breast Neoplasms (pathology)</term>
<term>Breast Neoplasms (therapy)</term>
<term>COVID-19 (complications)</term>
<term>COVID-19 (diagnosis)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (therapy)</term>
<term>COVID-19 Nucleic Acid Testing (MeSH)</term>
<term>COVID-19 Serological Testing (MeSH)</term>
<term>Dexamethasone (therapeutic use)</term>
<term>Drug Combinations (MeSH)</term>
<term>Female (MeSH)</term>
<term>Follow-Up Studies (MeSH)</term>
<term>Glucocorticoids (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (MeSH)</term>
<term>Immunization, Passive (MeSH)</term>
<term>Immunotherapy (MeSH)</term>
<term>Latent Infection (MeSH)</term>
<term>Lopinavir (therapeutic use)</term>
<term>Lung Neoplasms (complications)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Lung Neoplasms (therapy)</term>
<term>Male (MeSH)</term>
<term>Molecular Targeted Therapy (MeSH)</term>
<term>Neoplasms (complications)</term>
<term>Neoplasms (pathology)</term>
<term>Neoplasms (therapy)</term>
<term>Proportional Hazards Models (MeSH)</term>
<term>Risk Factors (MeSH)</term>
<term>Ritonavir (therapeutic use)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Spain (MeSH)</term>
<term>Time Factors (MeSH)</term>
<term>Virus Shedding (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term>
<term>AMP (usage thérapeutique)</term>
<term>Alanine (analogues et dérivés)</term>
<term>Alanine (usage thérapeutique)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Association médicamenteuse (MeSH)</term>
<term>Dexaméthasone (usage thérapeutique)</term>
<term>Espagne (MeSH)</term>
<term>Excrétion virale (MeSH)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Facteurs temps (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Glucocorticoïdes (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (MeSH)</term>
<term>Immunisation passive (MeSH)</term>
<term>Immunothérapie (MeSH)</term>
<term>Lopinavir (usage thérapeutique)</term>
<term>Modèles des risques proportionnels (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Ritonavir (usage thérapeutique)</term>
<term>Sujet âgé (MeSH)</term>
<term>Thérapie moléculaire ciblée (MeSH)</term>
<term>Tumeurs (anatomopathologie)</term>
<term>Tumeurs (complications)</term>
<term>Tumeurs (thérapie)</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (complications)</term>
<term>Tumeurs du poumon (thérapie)</term>
<term>Tumeurs du sein (anatomopathologie)</term>
<term>Tumeurs du sein (complications)</term>
<term>Tumeurs du sein (thérapie)</term>
<term>Études de suivi (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
<term>Antineoplastic Agents</term>
<term>Antiviral Agents</term>
<term>Dexamethasone</term>
<term>Glucocorticoids</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs</term>
<term>Tumeurs du poumon</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Breast Neoplasms</term>
<term>COVID-19</term>
<term>Lung Neoplasms</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term>
<term>Lung Neoplasms</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term>
<term>COVID-19</term>
<term>Lung Neoplasms</term>
<term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Tumeurs</term>
<term>Tumeurs du poumon</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
<term>Antinéoplasiques</term>
<term>Antiviraux</term>
<term>Dexaméthasone</term>
<term>Glucocorticoïdes</term>
<term>Lopinavir</term>
<term>Ritonavir</term>
<term>Tumeurs</term>
<term>Tumeurs du poumon</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>COVID-19 Nucleic Acid Testing</term>
<term>COVID-19 Serological Testing</term>
<term>Drug Combinations</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Hydroxychloroquine</term>
<term>Immunization, Passive</term>
<term>Immunotherapy</term>
<term>Latent Infection</term>
<term>Male</term>
<term>Molecular Targeted Therapy</term>
<term>Proportional Hazards Models</term>
<term>Risk Factors</term>
<term>SARS-CoV-2</term>
<term>Time Factors</term>
<term>Virus Shedding</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Association médicamenteuse</term>
<term>Espagne</term>
<term>Excrétion virale</term>
<term>Facteurs de risque</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hydroxychloroquine</term>
<term>Immunisation passive</term>
<term>Immunothérapie</term>
<term>Modèles des risques proportionnels</term>
<term>Mâle</term>
<term>Sujet âgé</term>
<term>Thérapie moléculaire ciblée</term>
<term>Études de suivi</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33735810</PMID>
<DateCompleted><Year>2021</Year>
<Month>05</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>05</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>148</Volume>
<PubDate><Year>2021</Year>
<Month>05</Month>
</PubDate>
</JournalIssue>
<Title>European journal of cancer (Oxford, England : 1990)</Title>
<ISOAbbreviation>Eur J Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.</ArticleTitle>
<Pagination><MedlinePgn>58-60</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0959-8049(21)00094-0</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2021.02.011</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rogado</LastName>
<ForeName>Jacobo</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain. Electronic address: jacobo.rogado@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gullón</LastName>
<ForeName>Pedro</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Public Health and Epidemiology Research Group, Universidad de Alcalá, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Obispo</LastName>
<ForeName>Berta</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Serrano</LastName>
<ForeName>Gloria</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lara</LastName>
<ForeName>Miguel Á</ForeName>
<Initials>MÁ</Initials>
<AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain; Universidad Complutense, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2021</Year>
<Month>02</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Eur J Cancer</MedlineTA>
<NlmUniqueID>9005373</NlmUniqueID>
<ISSNLinking>0959-8049</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber>
<NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>415SHH325A</RegistryNumber>
<NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber>
<NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber>
<NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000087123" MajorTopicYN="N">COVID-19 Nucleic Acid Testing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000087124" MajorTopicYN="N">COVID-19 Serological Testing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000085343" MajorTopicYN="N">Latent Infection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017201" MajorTopicYN="Y">Virus Shedding</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>Conflict of interest statement The authors declare no conflict of interest for the present work.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year>
<Month>01</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2021</Year>
<Month>01</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2021</Year>
<Month>02</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>3</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>3</Month>
<Day>18</Day>
<Hour>20</Hour>
<Minute>23</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33735810</ArticleId>
<ArticleId IdType="pii">S0959-8049(21)00094-0</ArticleId>
<ArticleId IdType="doi">10.1016/j.ejca.2021.02.011</ArticleId>
<ArticleId IdType="pmc">PMC7901370</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
</country>
<region><li>Communauté de Madrid</li>
</region>
<settlement><li>Madrid</li>
</settlement>
</list>
<tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Rogado, Jacobo" sort="Rogado, Jacobo" uniqKey="Rogado J" first="Jacobo" last="Rogado">Jacobo Rogado</name>
</region>
<name sortKey="Gull N, Pedro" sort="Gull N, Pedro" uniqKey="Gull N P" first="Pedro" last="Gull N">Pedro Gull N</name>
<name sortKey="Lara, Miguel" sort="Lara, Miguel" uniqKey="Lara M" first="Miguel" last="Lara">Miguel Lara</name>
<name sortKey="Obispo, Berta" sort="Obispo, Berta" uniqKey="Obispo B" first="Berta" last="Obispo">Berta Obispo</name>
<name sortKey="Serrano, Gloria" sort="Serrano, Gloria" uniqKey="Serrano G" first="Gloria" last="Serrano">Gloria Serrano</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000246 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000246 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:33735810 |texte= Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33735810" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |